BiotechTube
Stallergenes Greer

Stallergenes Greer

Antony, France· Est.
stallergenesgreer.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Stallergenes Greer is a global leader in allergy therapeutics, focusing exclusively on allergen immunotherapy (AIT). The company leverages a fully integrated model spanning R&D, manufacturing, and commercialization to address a growing global allergy market. Its strategy centers on advancing precision medicine in AIT, expanding its geographic footprint, and broadening its portfolio through internal development and acquisitions, such as the recent purchase of ENTOMON S.R.L. to boost venom immunotherapy capacity.

Allergy & ImmunologyRespiratory Diseases

Technology Platform

Allergen Immunotherapy (AIT) platform specializing in the standardization, purification, and formulation of natural allergen extracts for desensitization, with a focus on advancing precision medicine approaches.

Funding History

1
Series AUndisclosed

Opportunities

The global rise in allergy prevalence (affecting ~30% of the population) and increasing patient/physician preference for disease-modifying immunotherapy over symptomatic relief drive a large and growing market.
Expansion into new geographic regions and development of treatments for high-need areas like food allergies represent significant growth vectors.

Risk Factors

The company faces regulatory complexity for its biological products across different markets and potential reimbursement challenges.
Competition is intensifying from other AIT specialists and novel biologic drugs, while its reliance on natural allergen sources introduces supply chain vulnerability.

Competitive Landscape

Stallergenes Greer competes in the global AIT market with other specialized firms like ALK-Abelló and segments of larger pharma companies. It also faces indirect competition from pharmaceutical companies marketing symptomatic relief medications (antihistamines, corticosteroids) and biologic drugs for severe asthma. Its integrated manufacturing and broad portfolio are key differentiators.

More companies in Biologics / Biosimilars →More companies in France →